MLK
As MLKs (Mixed-Lineage Kinases) são um grupo de quinases que podem ativar várias vias de sinalização MAPK, incluindo JNK e p38, por meio da fosforilação de quinases MAP a montante (MAP2Ks). As MLKs estão envolvidas em respostas celulares ao estresse, apoptose e neuroinflamação. A desregulação da atividade das MLKs está associada a doenças neurodegenerativas e certos tipos de câncer. Na CymitQuimica, oferecemos uma gama de moduladores de MLK de alta qualidade para apoiar sua pesquisa em neurobiologia, resposta ao estresse e transdução de sinais.
Foram encontrados 22 produtos de "MLK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GW806742X
CAS:<p>GW806742X inhibits MLKL with Kd 9.3 μM, preventing necroptosis; also targets VEGFR2.</p>Fórmula:C25H22F3N7O4SPureza:98.3%Cor e Forma:SolidPeso molecular:573.55Anticancer agent 267
<p>Anticanceragent 267 (Compound 5q) serves as an activator of RIPK3 and MLKL. It effectively inhibits the proliferation of several cancer cell lines, with IC50 values of 9.79, 10.77, and 5.94 μM for MDA-MB-231, MDA-MB-486, and MCF-7, respectively. The compound induces cell cycle arrest at the subG1 phase and triggers necroptosis in MDA-MB-231 cells. Additionally, Anticanceragent 267 demonstrates antitumor activity in mouse xenograft models.</p>Fórmula:C13H11N5O4SCor e Forma:SolidPeso molecular:333.32PROTAC MLKL Degrader-1
<p>PROTAC MLKL Degrader-1 (Compound 36) is a selective PROTAC degrader targeting MLKL, achieving a degradation maximum (D max) over 90%.</p>Fórmula:C46H55F2N9O9SCor e Forma:SolidPeso molecular:948.05MLKL-IN-2
CAS:<p>MLKL-IN-2 is an MLKL inhibitor with potential tumorigenic activity for the study of cellular necrosis-related diseases.</p>Fórmula:C26H25N5OPureza:98.30%Cor e Forma:SolidPeso molecular:423.51KWCN-41
CAS:<p>KWCN-41, a RIPK1 inhibitor with 88 nM IC50, blocks necrosis, spares apoptosis, and is anti-inflammatory.</p>Fórmula:C18H17N3O2Cor e Forma:SolidPeso molecular:307.35NecroX-2
CAS:<p>NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.</p>Fórmula:C25H32N4O4S2Pureza:97.12%Cor e Forma:SolidPeso molecular:516.68PROTAC MLKL Degrader-2
<p>PROTAC MLKL Degrader-2, a PROTAC that targets MLKL (Mixed Lineage Kinase), incorporates the PROTAC target protein ligand, E3 ligase ligand Thalidomide, and PROTAC Linker N-Methylpiperazine. The conjugate of the E3 ubiquitin ligase ligand and Linker is Thalidomide-N-Methylpiperazine. This compound exhibits antinecroptotic activity in human cell lines and effectively degrades MLKL in the HT-29 xenograft mouse model.</p>Fórmula:C36H35N9O9SCor e Forma:SolidPeso molecular:769.78RIPK3-IN-3
<p>RIPK3-IN-3 (compound 20) is a selective RIPK3 inhibitor that demonstrates potent activity with an IC50 value of 10 nM.</p>Fórmula:C16H11N5SCor e Forma:SolidPeso molecular:305.36MLKL-IN-7
<p>MLKL-IN-7 (compound 9) is an MLKL inhibitor that exhibits anti-necrotic activity in HT-29 cells, with an IC50 value of 148.4 nM.</p>Fórmula:C21H15N5O5S2Peso molecular:481.05146Necrosulfonamide
CAS:<p>Necrosulfonamide ((E)-Necrosulfonamide) is a necroptosis inhibitor that targets MLKL and is selective. High-Quality, Low-Cost!</p>Fórmula:C18H15N5O6S2Pureza:98.85% - 99.49%Cor e Forma:SolidPeso molecular:461.47LY-364947
CAS:<p>LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.</p>Fórmula:C17H12N4Pureza:99.41% - 99.96%Cor e Forma:SolidPeso molecular:272.3AZ7550
CAS:<p>AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).</p>Fórmula:C27H31N7O2Pureza:97.07% - 99.75%Cor e Forma:SolidPeso molecular:485.58Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Fórmula:C20H28ClN7O3SPureza:99.85%Cor e Forma:SolidPeso molecular:482SZM-1209
CAS:<p>SZM-1209 is a potent and specific RIPK1 inhibitor with oral activity, displaying a dissociation constant (Kd) of 85 nM.</p>Fórmula:C31H29F5N4O5S2Pureza:98%Cor e Forma:SolidPeso molecular:696.71MLKL-IN-5
CAS:<p>MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis .</p>Fórmula:C18H20N6O4SCor e Forma:SolidPeso molecular:416.45IM-54
CAS:<p>IM-54 is a cell-permeable, effective, and selective necrosis inhibitor.</p>Fórmula:C19H23N3O2Pureza:99.24%Cor e Forma:SolidPeso molecular:325.4TC13172
CAS:<p>TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.</p>Fórmula:C17H16N4O5SPureza:98%Cor e Forma:SolidPeso molecular:388.4MLKL-IN-1
<p>MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.</p>Fórmula:C19H20N2O3Cor e Forma:SolidPeso molecular:324.37MLKL-IN-6
<p>MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.</p>Fórmula:C20H18N4O5Pureza:98%Cor e Forma:SolidPeso molecular:394.38Topoisomerase I/II inhibitor 8
CAS:<p>TopoisomeraseI/II inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of TopoisomeraseI/II that induces DNA damage and activates PARP-1, leading to the activation of RIPK1, RIPK3, and MLKL, ultimately causing necroptosis. It shows significant anticancer activity by effectively targeting cancer cell nuclei and inducing cell death through necroptosis, offering substantial clinical potential in overcoming resistance in cancer treatment.</p>Fórmula:C14H11Br2NO5S2Cor e Forma:SolidPeso molecular:497.179
